Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Public ClinicalTrials.gov record NCT03867097. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study identification
- NCT ID
- NCT03867097
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Civi Biopharma, Inc.
- Industry
- Enrollment
- 34 participants
Conditions and interventions
Interventions
- Iloprost Injection, for intravenous use Drug
- Placebo IV infusion Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2019
- Primary completion
- Aug 5, 2019
- Completion
- Aug 5, 2019
- Last update posted
- May 24, 2025
2019
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Arthritis & Rheumatology Research, PLLC | Phoenix | Arizona | 85032 | — |
| Pacific Arthritis Care Center of Los Angeles | Los Angeles | California | 90045 | — |
| Stanford University Medical Center | Palo Alto | California | 94305 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| Georgetown University Medical Center - Department of Rheumatology | Washington D.C. | District of Columbia | 20007 | — |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21224 | — |
| University of Michigan | Ann Arbor | Michigan | 48109-5422 | — |
| Robert Wood Johnson Medical School | New Brunswick | New Jersey | 08903 | — |
| Hospital for Special Surgery | New York | New York | 10021 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The University of Toledo Medical Center (UTMC) - Ruppert Health Center | Toledo | Ohio | 43614 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15261 | — |
| University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics | Houston | Texas | 77030 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Arthritis Northwest Rheumatology PLLC | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03867097, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 24, 2025 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03867097 live on ClinicalTrials.gov.